how does tirzepatide compare to other weight loss medications vs. Semaglutide: What You Should Know Tirzepatide as Compared with Semaglutide

Without resistance training and adequate protein, GLP1 patients risk long-term harm even as they look thinner

GLP-1 receptor agonists reduced the risk of major adverse cardiovascular events by 21% (HR, 0.79 [95% CI, 0.710.87]), with consistent effects in those receiving and not receiving an SGLT2 inhibitor at baseline (HR, 0.77 [95% CI, 0.541.09] and HR, 0.79 [95% CI, 0.710.87

If you develop concerning symptoms , contact your GP promptly

Calcium intake and risk of colon cancer in women and men

The transsulfuration pathway: a source of cysteine for glutathione in astrocytes

Differential effects of oral and intravenous l-carnitine on serum lipids: is the microbiota the answer